DALLAS, April 02, 2019 (GLOBE NEWSWIRE) -- via
OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts,
Inc.) (KALY) (“KALYâ€) today unveiled its
ongoing research and development of a cannabis treatment for Type 2
Diabetes. Kali-Extracts, through its patented cannabis
extraction process, is developing a variety of treatments for
various health issues. KALY recently published a research
report on its pilot cannabis treatment for Chronic Obstructive
Pulmonary Disease (COPD). Today, KALY is beginning to
disclose its additional research and development of cannabis
extracts for additional health issues. The company currently
has ongoing cannabis extract research and development targeting
four specific health issues, COPD and Type 2 Diabetes, and two
additional health issues KALY plans to announce later this week and
next week leading up to an online presentation with more detail on
each of the treatment developments later this month. The
market for Type 2 Diabetes is expected to be a $64 billion market by
2026. The market for COPD treatment is anticipated to
reach $14 billion by
2025.
In addition to its pharmaceutical developments, KALY is generating revenue from its patented cannabis extraction process delivering proprietary extracts for infusion into non-pharmaceutical commercial products. KALY announced last week finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion. KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (PURA) (“PURAâ€) leading EVERx CBD Sports Water. KALY has also recently announced plans to provide commercial extraction for Nouveau, Inc. (NOUV) (“NOUVâ€) in conjunction with NOUV’s recently announced 100-acre hemp farm.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/.
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), and as such, may involve
risks and uncertainties. These forward looking statements relate
to, amongst other things, current expectation of the business
environment in which the company operates, potential future
performance, projections of future performance and the perceived
opportunities in the market. The company's actual performance,
results and achievements may differ materially from the expressed
or implied in such forward-looking statements as a result of a wide
range of factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459